Re­vance touts first ther­a­peu­tic in­di­ca­tion for Botox ri­val Daxxi­fy in cer­vi­cal dys­to­nia

Re­vance Ther­a­peu­tics se­cured an FDA ap­proval on Mon­day for its Botox ri­val Daxxi­fy in cer­vi­cal dys­to­nia, mark­ing the drug’s first ther­a­peu­tic in­di­ca­tion.

Daxxi­fy was ap­proved …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER